As global bio companies fiercely compete to secure a leading position in cell and gene therapy (CGT) technologies, NanoEntek is set to accelerate the commercialization of its 'automated cell mass analysis robot.'
On July 3, NanoEntek announced that it is developing an 'automated cell mass analysis robot (Auto Sample Preparation)' that integrates its bioanalysis technologies, with plans for an official launch by the end of this year.
The development of this robot began at the request of major global pharmaceutical companies. It is characterized by maximizing functions required for real-world processes, based on feedback and on-site demands accumulated through ongoing collaboration. The robot can be used in a wide range of fields, from antibody therapeutics to cell therapy research and production. It is the world's first specialized system for cell counting?not a large general-purpose device?to automate the entire process from fluorescent staining to analysis of cells.
This robot is an all-in-one, fully automated cell analysis platform based on NanoEntek's existing multi-cell counter 'EVE-HT FL' series. It combines NanoEntek's proprietary Bio-MEMS (Bio-Micro Electro Mechanical Systems) technology with a seven-axis robotic system that utilizes linear motors and precision robotic pipetting technology, delivering speed, precision, and convenience.
NanoEntek expects this new product to become a game changer in the CDMO (Contract Development and Manufacturing Organization) market, where mass production is essential. The company already has supply references with major domestic CDMO company Samsung Biologics, as well as Johnson & Johnson, AstraZeneca, Galapagos, and Sanofi, and plans to quickly secure market leadership. With this, NanoEntek aims to establish a complete lineup of core bioanalysis equipment necessary for new drug development.
The most notable feature of this equipment is its ability to process up to 96 large-volume samples in just 15 minutes, from cell staining to counting and analysis, without any researcher intervention. Competing global equipment currently requires more than three hours to analyze the same volume of samples. In addition, while other high-end cell analysis devices require more than 170μl of sample per test, NanoEntek's device can perform precise analysis with as little as 20μl, achieving both research efficiency and cost savings.
A company representative stated, "This automated cell mass analysis robot is a bio-convergence robot equipped with speed, accuracy, and automation technologies. We expect it to bring innovative changes not only to the domestic market but also to global CDMO and biopharmaceutical research and production sites."
The representative added, "Given the high global demand, we plan to complete development within this year and actively target the global market."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
